# HackBio-cancer-internshipImmune Checkpoints in Cancer: 

Authors (@slack):Rahma mamdouh (rahma mam2000)

 immune checkpoints are crucial for regulating immune responses by ensuring that the immune system does not overreact and damage normal tissues. They describe PD-1 and CTLA-4 as key molecules that inhibit T-cell activity, which helps maintain self-tolerance and prevents autoimmunity. However, cancer cells can exploit these checkpoints to evade immune detection and continue to grow unchecked. By blocking these immune checkpoints with inhibitors, the natural immune response can be reactivated to target and eliminate cancer cells more effectively. This approach has shown significant promise in improving treatment outcomes for various types of cancer

.Mechanisms of Immune Checkpoints

Immune checkpoints function primarily by modulating T cell activity. PD-1, a receptor on T cells, binds to its ligands PD-L1 or PD-L2 on other cells, inhibiting T cell activation and proliferation to limit the immune response. CTLA-4, another checkpoint molecule, competes with the costimulatory receptor CD28 for binding to B7 molecules (CD80 and CD86) on antigen-presenting cells, reducing T cell activation. These mechanisms are essential for preventing hyperactive immune responses that could damage normal tissues.

Immune Evasion by Cancer Cells

Cancer cells often exploit these immune checkpoint pathways to avoid immune detection. Many tumors express high levels oPD-L1, which binds to PD-1 on T cells, leading to T cell exhaustion and preventing effective immune responses against cancer cells. Similarly, tumors can upregulate molecules that activate CTLA-4, further inhibiting T cell responses and allowing the cancer to evade immune surveillance and continue growing.

Case Study from "Cancer Immunotherapy Using Checkpoint Blockade" (Ribas & Wolchok, 2018)

In their 2018 paper, Ribas and Wolchok discuss the case of a 54-year-old patient with advanced melanoma who was treated with pembrolizumab, an anti-PD-1 checkpoint inhibitor. The patient had previously undergone multiple lines of therapy, including chemotherapy and targeted therapy, with limited success. Upon receiving pembrolizumab, the patient experienced significant tumor shrinkage within three months, with a notable reduction in tumor size as observed in imaging studies. Additionally, the patient reported improved quality of life and extended progression-free survival. This case illustrates the potential of pembrolizumab to achieve durable responses in patients who have exhausted other treatment options, emphasizing the impact of immune checkpoint inhibitors in modern cancer therapy.

Conclusion

The development of immune checkpoint inhibitors marks a significant advancement in cancer treatment, offering new hope for patients. Continued research into immune checkpoints and their interactions will be crucial for improving existing treatments and discovering new strategies to combat cancer more effectively.

Reference  

 1- Zhou, Y., Wang, F., Li, G., Xu, J., Zhang, J., Gullen, E., Yang, J., & Wang, J. (2024). From immune checkpoints to therapies: Understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer. \\\*Frontiers in Immunology, 15,\\\* 1340307. https\\://doi.org/10.3389/fimmu.2024.1340307

2- Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. \\\*Science, 359\\\*(6382), 1350-1355. https\\://doi.org/10.1126/science.aar4060

3- Jiang, Y., & Geng, X. (2020). Immune checkpoint inhibitors: Mechanism of action, efficacy, and safety. \\\*Journal of Hematology & Oncology, 13\\\*(1), 1-13. https\\://doi.org/10.1186/s13045-020-00913-w
